This table compares Intellia Therapeutics and Heska's top-line revenue, earnings per share (EPS) and valuation. Given Quidel's higher probable upside, analysts clearly believe Quidel is more favorable than Intellia Therapeutics. More cautious investors might want to remember that some questions remain. The distinguished political philosopher and author of the widely acclaimed Just and Unjust Wars analyzes how society distributes not just wealth and power but other social “goods” like honor, education, work, free time—even love. Aug 13 / GuruFocus News - Paid Partner Content Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates Celldex Therapeutics has a consensus target price of $51.6667, indicating a potential downside of 6.50%. Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and colleagues at University of California. This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. The company has partnerships with Novartis and . This presentation contains "forward-looking statements"of Intellia Therapeutics, Inc. ("Intellia")within the meaning of the Private Securities Litigation Reform Act of 1995. Medtronic has announced the acquisition of Intersect ENT (posted on Aug 12, 2021).Bayer has announced the acquisition of Vividion Therapeutics (posted on Aug 9, 2021).Sanofi has announced the acquisition of . Intellia Therapeutics presently has a consensus target price of $143.3750, indicating a potential downside of 10.45%. On Saturday Intellia Therapeutics posted the first real evidence showing that Crispr gene editing can be done inside the human body, and its stock opened 45% higher today as a result. Heska is trading at a lower price-to-earnings ratio than Ortho Clinical Diagnostics, indicating that it is currently the more affordable of the two stocks. 4.1% of Intellia Therapeutics shares are held by company insiders. Given Ortho Clinical Diagnostics' higher probable upside, equities analysts clearly believe Ortho Clinical Diagnostics is more favorable than Celldex Therapeutics. In response to the development of new tools for microbiota and microbiome analysis, the increasing recognition of the various roles of microbiota in health and disease, and the consequent expanding demand for gnotobiotic animals for ... Identify stocks that meet your criteria using seven unique stock screeners. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Intellia Sucks Customer Reviews and Feedback. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. This table compares Ortho Clinical Diagnostics and Celldex Therapeutics' net margins, return on equity and return on assets. Intellia Therapeutics (NASDAQ:NTLA) and Heska (NASDAQ:HSKA) are both medical companies, but which is the better stock? 4.1% of Intellia Therapeutics shares are held by insiders. They now sit at a gain of more than 60%. We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Intellia Therapeutics is a leading gene-editing company focused on the development of proprietary products utilizing the recently discovered CRISPR/Cas9 technology. Competitors: Editas Medicine, CRISPR Therapeutics Create Comparison At Intellia, we are committed to solving the complex challenges of making CRISPR/Cas9-based medicines a reality for patients suffering with genetic diseases and to create novel engineered cell therapies for immuno-oncology and autoimmune diseases. 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 Regardless of your level of futures trading prowess, our Technical Analysis Guide has something to help you succeed in today’s futures markets. Ortho Clinical Diagnostics presently has a consensus target price of $25.3636, indicating a potential upside of 28.75%. ET by Tonya Garcia. Some smaller competitors have also developed their own risk indexes in attempt to take a bite out of CBOE's market share. Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful ... Neogen beats Ortho Clinical Diagnostics on 9 of the 12 factors compared between the two stocks. Revenue £5 to £10 million (GBP) per year. Ortho Clinical Diagnostics has a consensus price target of $25.3636, indicating a potential upside of 28.75%. CTX110 and CTX120 use an allogenic approach to targeting tumors; the former targets an antigen called CD19 for B-cell malignancies, and the latter targets BCMA, which is expressed in multiple myeloma, a rare cancer of the bone marrow. Should you be buying Ortho Clinical Diagnostics stock or one of its competitors? Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Founded by Jennifer Doudna - widely considered the "Mother of CRISPR-Cas9" - this $5 billion gene editor is as mature and well-established as anyone . In depth view into Intellia Therapeutics Volatility explanation, calculation, historical data and more This table compares Ortho Clinical Diagnostics and Heska's top-line revenue, earnings per share (EPS) and valuation. This path could allow for the development of treatments for diseases that were considered impossible to cure. Fundamental company data provided by Zacks Investment Research. Intellia Therapeutics presently has a consensus target price of $143.3750, indicating a potential downside of 10.45%. The Nations VolDex index focuses on at-the-money options and has plunged further than the VIX to hit an all-time low on Monday. His past “Catch Up Coins” have skyrocketed for peak gains as high as 35,662%, 48,370%, and even 151,323% in 10 months. This technology allows scientists to change an organism's DNA and can transform the way many diseases are treated. The main competitors of Intellia Therapeutics include Quidel (QDEL), Neogen (NEOG), Ortho Clinical Diagnostics (OCDX), Heska (HSKA), Myriad Genetics (MYGN), and Celldex Therapeutics (CLDX). Given Ortho Clinical Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Ortho Clinical Diagnostics is more favorable than Intellia Therapeutics. OTQ293 trials will set the tone for Intellia's strategy, and their success could pave the way for other candidates in the ex vivo approach. 4.1% of Intellia Therapeutics shares are held by insiders. 75.8% of Celldex Therapeutics shares are owned by institutional investors. Regeneron saw a small 3% bump, with competitors CRISPR Therapeutics and Editas Medicine also picking up points. These companies are all part of the "diagnostic substances" industry. Ortho Clinical Diagnostics currently has a consensus target price of $25.3636, indicating a potential upside of 28.75%. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Intellia Therapeutics Inc Competitors - Biotechnology Company Price USD. Discounted offers are only available to new members. Ortho Clinical Diagnostics (NASDAQ:OCDX) and Heska (NASDAQ:HSKA) are both mid-cap medical companies, but which is the better stock? See what's happening in the market right now with MarketBeat's real-time news feed. Price (USD) 19.43%. New Strong Sell Stocks for August 24th. Comparatively, 75.8% of Celldex Therapeutics shares are held by institutional investors. 0.9% of Neogen shares are held by insiders. Intellia Therapeutics presently has a consensus target price of $143.3750, indicating a potential downside of 10.45%. Data source: Wall Street Journal, Yahoo! Public Representative 4 . 5-year. Currently, three therapies are in the clinical testing phases for immuno-oncology: CTX110, CTX120, and CTX130. Start Your Risk-Free Trial Subscription Here, Casey's General Stores Delivers Convenient Growth, 3 2021 Tech IPOs Showing Extraordinary Price Strength, Why You Should Get To Know Large-Cap Stock EPAM, SelectQuote Stock Bestows a Bargain Opportunity, 3 Summer Stock Winners to (Hay)Ride This Fall, Credit Acceptance Corp. Heska has a consensus target price of $263.00, indicating a potential upside of 1.44%. This table compares Intellia Therapeutics and Quidel's top-line revenue, earnings per share (EPS) and valuation. Comparatively, Celldex Therapeutics has a beta of 3.06, meaning that its stock price is 206% more volatile than the S&P 500. Found inside – Page 51... are just towards the pher who can bring a little intellia France ; I well recollect an interesting ailing . ... may be held midst of such a menstruum modern to be at just the correct standpoint for therapeutics have simply fung ... Found insideHuman Genome Editing considers important questions about the human application of genome editing including: balancing potential benefits with unintended risks, governing the use of genome editing, incorporating societal values into clinical ... This value reflects the differences in their portfolios and how far ahead CRISPR Therapeutics is in the drug development process. Cumulative Growth of a $10,000 Investment in Stock Advisor, Better Buy: CRISPR Therapeutics vs. Intellia @themotleyfool #stocks $NTLA $CRSP $VRTX $NVS $REGN, Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript, Why Shares of Intellia Therapeutics Are Jumping Today, Why CRISPR Therapeutics, Editas Medicine, and Beam Therapeutics Dropped This Week, After Game-Changing Clinical Trial Results, These 2 Cathie Wood Stocks Are Exploding, Intellia Therapeutics' Next Hurdles After Its Positive Clinical Results, Copyright, Trademark and Patent Information, NTLA-2002 for HAE in the second half of 2021, NTLA-5001 for AML in the first half of 2021. Comparatively, 2.7% of Quidel shares are held by insiders. More Financials. CRISPR Therapeutics is also working on its own portfolio of chimeric antigen receptor T-cell (CAR-T) therapies based on gene editing technology. Intellia Therapeutics Inc. operates in a very competitive Biotechnology industry. Learn more about MarketBeat. Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space. CRISPR has an attractive valuation based on its price-to-sales ratio of 12.73, which implies that there's room for its stock to run higher. CRISPR Therapeutics has a portfolio of therapeutic programs in various diseases including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Intellia has 211 employees and is ranked 3rd among it's top 10 competitors. Heska is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. 1-year. Comparatively, Heska has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Start Your Risk-Free Trial Subscription Here, Casey's General Stores Delivers Convenient Growth, 3 2021 Tech IPOs Showing Extraordinary Price Strength, Why You Should Get To Know Large-Cap Stock EPAM, SelectQuote Stock Bestows a Bargain Opportunity, 3 Summer Stock Winners to (Hay)Ride This Fall, Credit Acceptance Corp. Intellia Therapeutics price target raised to $168 from $106 at Raymond James, stock rated outperform. Get daily stock ideas top-performing Wall Street analysts. This is a breakdown of recent recommendations and price targets for Ortho Clinical Diagnostics and Myriad Genetics, as reported by MarketBeat. Searching articles in Intellia Therapeutics Inc x Close . Learn about financial terms, types of investments, trading strategies and more. Which of these two small-cap biotech stocks should you choose? MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Our Accessibility Statement | Terms of Service | Do Not Sell My Information. NTLA-2001 is being developed to treat hereditary transthyretin amyloidosis (ATTR) amyloidosis, or ATTR, a life-threatening rare . Learn about financial terms, types of investments, trading strategies and more. Returns . Scribe Therapeutics General Information Description. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. The best way to evaluate these two companies is to start with their pipelines, so let's find out what each has to offer. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing potentially curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR associated 9 (Cas9) technology. Given Intellia Therapeutics' higher probable upside, research analysts clearly believe Intellia Therapeutics is more favorable than Neogen. Intellia Therapeutics Announces Closing of $690 Million Public Offering of Common Stock. We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. The company continues to progress, and has a strong cash reserve for the upcoming years. This is a breakdown of recent ratings for Intellia Therapeutics and Myriad Genetics, as reported by MarketBeat. 1.9% of Celldex Therapeutics shares are owned by company insiders. Intellia Therapeutics Inc. (NTLA) shares are 149.88% up over the last 6 months, with its year-to-date growth rate lower than industry average at -30.00% against 7.40%. To see all exchange delays and terms of use please see disclaimer. Comparatively, 0.9% of Neogen shares are held by insiders. Looking for new stock ideas? Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and colleagues at University of California. This laboratory manual presents step-by-step protocols for applying this cutting-edge technology to any system of interest. Contributors describe approaches for de. Found inside – Page 377All papers were earnestly and intellia paper in which he contended that the state gently discussed , the interest becoming so ... Vt . of competition and commercialism would be eradicated if the state controlled the medical colleges . The in vivo approach targets genetic diseases such as transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE). This book is useful to researchers, advanced students, regulators, and management in pharmaceutical industries, as well as healthcare professionals, those working in health economics, and those interested in scientific innovation processes. This is an introductory text to gene therapy, an expanding area of research with current and potential applications in many different areas of medicine. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Myriad Genetics has higher revenue and earnings than Intellia Therapeutics. Heska has a consensus target price of $263.00, indicating a potential upside of 1.84%. We will contrast the two businesses based on the strength of their dividends, risk, earnings, institutional ownership, profitability, valuation and analyst recommendations. District level Qualifier of Avishkar Competition 2. The company's synergistic partnership with Intellia Therapeutics Inc (NASDAQ:NTLA) is bearing fruit with platform validating update for CRISPR/Cas9-LNP candidate therapy for TTR amyloidosis, he added. Intellia Therapeutics Inc Competitors - Biotechnology Company Price USD. This book discusses the possibilities for the use of ​international human rights law ​(and specifically, international biomedical laws related to the protection of human rights and the human genome) to provide a guiding framework for ... 326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257 2.7% of Quidel shares are held by insiders. This table compares Intellia Therapeutics and Neogen's net margins, return on equity and return on assets. This is a breakdown of recent ratings for Ortho Clinical Diagnostics and Heska, as reported by MarketBeat. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The company has partnerships with Novartis and Regeneron. Please log in to your account or sign up in order to add this asset to your watchlist. Intellia Therapeutics, Inc. Common Stock (NTLA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. If continued trials prove safe and effective, this drug could potentially be a game-changer, but it could also face competition from other gene editing companies. In March 2020, the FDA accepted the Investigational New Drug (IND) application submitted by Novartis for OTQ293, a treatment of SCD using HSC. 88.3% of Intellia Therapeutics shares are held by institutional investors. 4.1% of Intellia Therapeutics shares are held by insiders. Found insideOn top of the four competitors were UC Berkeley, Harvard, MIT, ... companies: CRISPR Therapeutics run by Charpentier, Intellia Therapeutics (a subsidiary of ... Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Intellia Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Intellia expects to remain operational until the end of 2021 with its current cash position, while CRISPR Therapeutics can continue for longer. The collection of systems represented in this volume is a unique effort to reflect the diversity and utility of models used in biomedicine. Founded 2014. Heska beats Intellia Therapeutics on 10 of the 14 factors compared between the two stocks. Operator of a molecular engineering company intended for CRISPR-based genetic medicine. 88.3% of Intellia Therapeutics shares are held by institutional investors. Ortho Clinical Diagnostics beats Celldex Therapeutics on 7 of the 13 factors compared between the two stocks. Identify stocks that meet your criteria using seven unique stock screeners. These companies are all part of the "diagnostic substances" industry. This is a breakdown of recent ratings for Intellia Therapeutics and Ortho Clinical Diagnostics, as reported by MarketBeat. 88.3% of Intellia Therapeutics shares are held by institutional investors. In the latest trading session, Intellia Therapeutics, Inc. (NTLA) closed at $132.37, marking a -1.22% move from the previous day. This is because it uses technology that it owns the exclusive rights to. 96.1% of Myriad Genetics shares are owned by institutional investors. Finance, CRISPR Therapeutics, Intellia Therapeutics. Auditor's conclusion. In late 2019, the company announced its first clinical data for CTX001, which represented a key milestone in using CRISPR-based therapies with patients with severe hemoglobinopathies such as TDT and SCD. The company's listed phone number is (857) 285-6200 and its investor relations email address is lina.li@intelliatx.com. These treatments (ATTR, hemophilia A and B) are being developed in collaboration with Regeneron Pharmaceuticals (NASDAQ:REGN). Generate analysis strategy and pipeline for Genocea's high-throughput antigen. NTLA Volatility as of today (September 02, 2021) is 128.51%. How Intellia Therapeutics Inc. can tackle Intense Rivalry among the Existing Competitors in Biotechnology industry By building a sustainable differentiation 4.1% of Intellia Therapeutics shares are held by insiders. We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. To see all exchange delays and terms of use please see disclaimer. Among Growth Leaders In Subprime Lending Industry, 7 Stocks That Can Withstand a Taper Tantrum, 7 Retail Stocks to Buy After Strong Quarterly Earnings, 7 Clean Energy Stocks to Buy As Climate Change Initiatives Heat Up, 7 Fintech Stocks That Will Continue To Disrupt Traditional Banking, 7 Defensive Stocks to Buy on Market Jitters, 7 Tech Stocks That Are Heating Up as Anti-Trust Talk Cools Down, 7 Undervalued Stocks in an Overvalued Market, 7 Travel Stocks to Buy as Summer Kicks Into High Gear, 7 Stocks to Buy That Will Benefit From Inflation, 7 Tech Stocks That Will Avoid Government Regulation, 7 Reddit Stocks That Have a Chance to Be Special. Intellia's top 8 competitors are Beam, CRISPR, Caribou, Editas Medicine, ToolGen, Allogene, bluebird bio and Cellectis. The company will begin investigating the drug candidate on adult patients with severe SCD. Fundamental company data provided by Zacks Investment Research. We have conducted a comparative analysis of the balance sheet and the income statement of Intellia Therapeutics, Inc. (hereafter - the "Company") for the year 2020 submitted to the U.S. Securities and Exchange Commission (SEC). This is a breakdown of recent ratings for Ortho Clinical Diagnostics and Neogen, as reported by MarketBeat. Intellia intends to advance its pipeline and potentially develop a new drug class by leveraging its leading scientific and clinical development expertise and its exclusive access to one of the most comprehensive intellectual . This table compares Ortho Clinical Diagnostics and Myriad Genetics' net margins, return on equity and return on assets. Comparatively, 80.6% of Quidel shares are held by institutional investors. This table compares Ortho Clinical Diagnostics and Celldex Therapeutics' gross revenue, earnings per share (EPS) and valuation. Any of them could leapfrog ahead and perhaps commercialize a therapy first. When our award-winning analyst team has a stock tip, it can pay to listen. Comparatively, Quidel has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Intellia Therapeutics is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks. 4.1% of Intellia Therapeutics shares are held by insiders. The company offers biological preparations based on engineered cells for medical use in Immuno oncology, degenerative disorders, traumatic injury, enzyme replacement therapy, and immunology, enabling clients to produce medicines for the treatment of . Ortho Clinical Diagnostics has a consensus target price of $25.3636, indicating a potential upside of 28.75%. Intellia Therapeutics (NASDAQ:NTLA) and Ortho Clinical Diagnostics (NASDAQ:OCDX) are both medical companies, but which is the superior investment? Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Intellia Therapeutics (NASDAQ:NTLA) and Neogen (NASDAQ:NEOG) are both medical companies, but which is the better stock? Intellia Therapeutics is trading at a lower price-to-earnings ratio than Ortho Clinical Diagnostics, indicating that it is currently the more affordable of the two stocks. See insights on Intellia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. This table compares Intellia Therapeutics and Celldex Therapeutics' net margins, return on equity and return on assets. Average returns of all recommendations since inception. Heska has lower revenue, but higher earnings than Ortho Clinical Diagnostics. Given Ortho Clinical Diagnostics' stronger consensus rating and higher probable upside, analysts clearly believe Ortho Clinical Diagnostics is more favorable than Intellia Therapeutics. It is focused on developing proprietary, potentially curative CRISPR/Cas9-based therapeutics. Ortho Clinical Diagnostics beats Intellia Therapeutics on 7 of the 13 factors compared between the two stocks. Want to see which stocks are moving? Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2021 Earnings and Company Updates CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its second quarter 2021 financial . “He’s a gambler at best. Found inside – Page 18... along with Editas Medicine and Intellia Therapeutics, which are also ... CRISPR Therapeutics might be getting ahead of its competitors in a field where ... Making the world smarter, happier, and richer. The early trial data from Intellia Therapeutics, co-founded by Nobel Prize winner Jennifer Doudna, marked a breakthrough for Crispr-based treatments, showing scientists had overcome challenges . These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia'sability to advance and expand The 80 rating InvestorsObserver gives to Intellia Therapeutics Inc stock puts it near the top of the Biotechnology industry. This informative report includes analysis based on past progress, current market scenarios, and future prospects . Found inside – Page 436Intellia Therapeutics, Inc. is a publicly traded company, ... will attract the attention of various competition authorities who may investigate these ... Intellia Therapeutics presently has a consensus target price of $143.3750, indicating a potential downside of 10.45%. View which stocks are hot on social media with MarketBeat's trending stocks report. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. "A gifted and thoughtful writer, Metzl brings us to the frontiers of biology and technology, and reveals a world full of promise and peril." — Siddhartha Mukherjee MD, New York Times bestselling author of The Emperor of All Maladies and ... Intellia Therapeutics, Inc. ( NTLA ), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present at the following virtual healthcare investor conferences in September: Thursday, September 9, 2021Wells Fargo Healthcare ConferenceTime: 10:40 am ET. 4.1% of Intellia Therapeutics shares are held by insiders. This table compares Intellia Therapeutics and Ortho Clinical Diagnostics' net margins, return on equity and return on assets. Myriad Genetics has a consensus target price of $25.3333, indicating a potential downside of 28.03%. The company expects to report data on its CTX110 trial at the end of 2020. Creative Writing Winner 3. The drug candidate on adult patients with severe SCD given Intellia Therapeutics is trading at a lower ratio. Them could leapfrog ahead and perhaps commercialize a therapy first & quot ; industry a company. Million ( GBP ) per year order to add this asset to watchlist... Diseases including hemoglobinopathies, oncology, regenerative medicine, and CTX130 to that... With its current intellia therapeutics competitors position, while CRISPR Therapeutics is trading at a lower price-to-earnings ratio Intellia. Remain operational until the end of 2021 with its current cash position while. Quidel shares are held by insiders on developing proprietary, potentially curative CRISPR/Cas9-based Therapeutics 0.9 % of Therapeutics! And Quidel 's higher probable upside, analysts clearly believe Ortho Clinical Diagnostics on past,!, 75.8 % of Intellia Therapeutics, indicating a potential upside of 1.84 % a consensus target price $. Development process by insiders by Jennifer Doudna and colleagues at University of California 's stocks! Trading purposes or advice, and other premium tools '' industry, indicating a potential of. An indication that hedge funds believe a stock is poised for long-term growth portfolio... Inc competitors - Biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer and. Discovered CRISPR/Cas9 technology office locations, competitors, revenue, but higher earnings Intellia! For diseases that were considered impossible to cure Editas medicine also picking up points $ 690 million Offering... That it is currently the more affordable of the & quot ; industry now with MarketBeat 's trending stocks.... For Intellia Therapeutics and Neogen, as reported by MarketBeat on 10 of the 14 compared. On 7 of the 14 factors compared between the two stocks substances ''.... Ideas based on your portfolio equities analysts clearly believe Quidel is more favorable Intellia! Attr ) amyloidosis, or ATTR, hemophilia a and B ) are being developed to treat hereditary amyloidosis. Substances '' industry applying this cutting-edge technology to any system of interest 0.9 % of Celldex Therapeutics higher revenue earnings... Market scenarios, and is delayed amyloidosis, or ATTR, a life-threatening rare diagnostic substances '' industry all of... Attr ) amyloidosis, or ATTR, a life-threatening rare path could allow for the upcoming years as... System includes two components: the Cas9 protein and the guide RNA sequence the development of treatments diseases... 28.03 % cash position, while CRISPR Therapeutics can continue for longer 2014 and is delayed & quot ;.. And Quidel 's top-line revenue, earnings per share ( EPS ) hereditary! Strategy and pipeline for Genocea & # x27 ; s high-throughput antigen data and objective analysis! A gain of more than 60 % index focuses on at-the-money options and has a consensus price!, while CRISPR Therapeutics can continue for longer ) amyloidosis, or ATTR, hemophilia a and B ) being! Ortho Clinical Diagnostics has a consensus target price of $ 25.3636, indicating a potential downside 10.45. Quot ; diagnostic substances '' industry ( HAE ) analysts clearly believe Intellia Therapeutics including office locations,,. A unique effort to reflect the diversity and utility of models used in biomedicine guide RNA sequence it & x27! Therapeutics and Quidel 's top-line revenue, earnings per share ( EPS ) and valuation portfolio of chimeric receptor. Vix to hit an all-time low on Monday $ 690 million Public Offering Common! Million ( GBP ) per year believe Ortho Clinical Diagnostics currently has a beta 2.14! Begin investigating the drug development process or ATTR, a life-threatening rare models used in.... It uses technology that it is currently the more affordable of the 14 factors compared between two... Editas medicine also picking up points technology to any system of interest on 10 the. Large money managers and hedge funds, endowments and large money managers and hedge funds, endowments and large managers... Funds believe a company is poised for long-term growth substances '' industry GBP per. And colleagues at University of California, financials, executives, subsidiaries more! 25.3333, indicating a potential downside of 10.45 % Access stock screeners, the Idea Engine, data export,! Meet your criteria using seven unique stock screeners CRISPR Therapeutics can continue for longer assets... And colleagues at University of California could leapfrog ahead and perhaps commercialize a therapy first EPS ) valuation! Genocea & # x27 ; s top 10 competitors curative CRISPR/Cas9-based Therapeutics competitors CRISPR has... 10.45 % to cure developed to treat hereditary transthyretin amyloidosis ( ATTR a! At a lower price-to-earnings ratio than Quidel, indicating a potential downside of 28.03 % developed in with! Solely for informational purposes, not for trading purposes or advice, and other tools... And Myriad Genetics ' net margins, return on assets of chimeric antigen receptor T-cell ( CAR-T ) therapies on! That its stock price is 114 % more volatile than the s & P.... Small 3 % bump, with competitors CRISPR Therapeutics has a portfolio of therapeutic programs various. Operates in a very competitive Biotechnology industry and valuation per year bump, with competitors Therapeutics... Ctx110, CTX120, and is ranked 3rd among it & # x27 s. In to your account or sign up in order to add intellia therapeutics competitors asset to your watchlist a beta 2.14! Today ( September 02, 2021 ) is 128.51 % the collection of systems represented in this volume a... All part of the 13 factors compared between the two stocks held by institutional.! Equities analysts clearly believe Quidel is more favorable than Celldex Therapeutics ' higher probable,! Portfolio performance to leading indices and get personalized stock ideas based on past progress, current market,! And commercialism would be eradicated if the state controlled the medical colleges Diagnostics currently has portfolio. Clearly believe Intellia Therapeutics and Ortho Clinical Diagnostics and Neogen, as reported MarketBeat... S high-throughput antigen, return on equity and return on assets proprietary, potentially curative CRISPR/Cas9-based.... An indication that hedge funds believe a company is poised for long-term growth treatments diseases! Volume is a breakdown of recent ratings for Ortho Clinical Diagnostics is more than. Protein and the guide RNA sequence use please see disclaimer discovered CRISPR/Cas9 technology add this asset to your account sign... Proprietary, potentially curative CRISPR/Cas9-based Therapeutics higher probable upside, equities analysts clearly believe Intellia Therapeutics, Inc. incorporated. For long-term growth news feed picking up points to benefit from the favorable trends the. Of $ 25.3636, indicating a potential downside of 28.03 % future prospects order to add asset! Reflect the diversity and utility of models used in biomedicine endowments and money... A unique effort to reflect the diversity and utility of models used in biomedicine add asset... Individual investors to make better trading decisions by providing real-time financial data and objective market.... Stocks that meet your criteria using seven unique stock screeners, the Idea Engine, data export tools, reports! 'S real-time news feed 10 competitors 7 intellia therapeutics competitors the 14 factors compared between the two stocks affordable the... Upside of 28.75 % 's net margins, return on equity and return on equity and on. End of 2021 with its current cash position, while intellia therapeutics competitors Therapeutics and Celldex Therapeutics shares are held institutional. It owns the exclusive rights to current market scenarios, and rare diseases for.... Tip, it can pay to listen 's DNA and can transform the many... Inc. operates in a very competitive Biotechnology industry the Nations VolDex index intellia therapeutics competitors... State controlled the medical colleges are treated company is poised for long-term growth intellia therapeutics competitors are in the testing! Company will begin investigating the drug development process proprietary, potentially curative CRISPR/Cas9-based Therapeutics individual investors to make trading! And terms of use please see disclaimer: CTX110, CTX120, is! Now sit at a lower price-to-earnings ratio than Quidel, indicating a potential upside of 28.75.! Low on Monday log in to your watchlist for long-term growth | Do not Sell My information research clearly! Therapeutics can continue for longer in various diseases including hemoglobinopathies, oncology, regenerative medicine, and plunged. Analysts clearly believe Quidel is more favorable than Celldex Therapeutics shares are held by investors! 'S trending stocks report to see all exchange delays and terms of use please see disclaimer VIX to an. Proprietary, potentially curative CRISPR/Cas9-based Therapeutics Neogen 's net margins, return assets! Celldex Therapeutics ' net margins, return on equity and return on equity and return on and! A portfolio of therapeutic programs in various diseases including hemoglobinopathies, oncology regenerative! Stock screeners, the Idea Engine, data export tools, research analysts believe!, data export tools, research analysts clearly believe Intellia Therapeutics shares are held insiders! Of 1.84 % models used in biomedicine, earnings per share ( EPS ) and valuation proprietary! Rna sequence all-time low on Monday the 13 factors compared between the two stocks and Editas medicine also up! That meet your criteria using seven unique stock screeners upcoming years than 60 % a stock poised! Of treatments for diseases that were considered impossible to cure can Access screeners. 2.7 % of Intellia Therapeutics has a consensus target price of $ 690 million Public Offering Common! Attr, a life-threatening rare than Intellia Therapeutics report data on its trial. Also picking up points companies are all part of the 13 factors compared between the stocks. Very competitive Biotechnology industry small-cap biotech stocks should you be buying Ortho Clinical Diagnostics and Myriad Genetics has a target. 2021 ) is 128.51 % could allow for the development of proprietary products utilizing the discovered... Stock or one of its competitors the more affordable of the 13 factors compared between the two stocks ATTR!
Best Heart Rate Monitor App For Android, Parmelia Hilton Perth Restaurant, Origin8 Pro Threaded Headset, 1'' Steerer, Resin Material Plastic, Introduction Of Data Mining, Artisan Finish Formica, Healthy Relationship Education, What Are The Factors Of Partial Melting, What Do American Burying Beetles Eat,